14 December 2017 
EMA/CHMP/811414/2017 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Taltz 
ixekizumab 
On 14 December 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Taltz. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted a new indication  as follows: 
" Psoriatic arthritis  
Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis 
in adult patients who have responded inadequately to, or who are intolerant to one or more disease-
modifying anti-rheumatic drug (DMARD) therapies.” 
For information, the full indication(s) for Taltz will be as follows: 
Plaque psoriasis 
Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates 
for systemic therapy. 
Psoriatic arthritis  
Taltz, alone or in combination with methotrexate, is indicated for the treatment of active 
psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant 
to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
  
 
 
 
  
                                                
